#United States #Class Action #Berger Montague #Gaithersburg #Altimmune

Berger Montague Investigates Altimmune Inc. Claims

In an important development for investors, Berger Montague PC, a national plaintiffs' law firm, has initiated a class action lawsuit against Altimmune Inc. (NASDAQ: ALT). This legal action comes on the heels of significant issues that arose during the company's recent clinical trials. Investors who purchased shares between August 10, 2023, and June 25, 2025, are encouraged to evaluate their options and consider stepping forward as potential lead plaintiffs in this case.

Background on Altimmune Inc.

Altimmune is a clinical-stage biopharmaceutical company based in Gaithersburg, Maryland, known for its innovative approaches to treating obesity and liver diseases. Among its notable projects is the development of therapies for metabolic dysfunction-associated liver conditions, including MASH (metabolic dysfunction-associated steatohepatitis). However, recent events have raised considerable alarm among investors.

Recent Developments

On June 26, 2025, Altimmune released press statements regarding the outcomes of its IMPACT Phase 2b trial for Pemvidutide, a key treatment aimed at addressing MASH. Despite prior confidence expressed by the company's management, the results revealed that the primary endpoint for fibrosis reduction did not achieve statistical significance. The increase in placebo response was cited as a contributing factor to this disappointing outcome.

In response to this announcement, Altimmune's stock plummeted dramatically, falling by over 53% in a single trading day. On June 25, shares closed at $7.71 but plummeted to a mere $3.61 the following day. This catastrophic drop has left shareholders reeling, prompting the initiation of legal proceedings by Berger Montague.

Legal Actions and Deadlines

Investors who believe they might have been negatively impacted by this situation have a deadline of October 6, 2025, to seek the role of lead plaintiff in this class action. Berger Montague is actively reaching out to these investors, encouraging them to understand their rights and opportunities to take action.

If you are an affected investor, you can contact Berger Montague representatives Andrew Abramowitz or Caitlin Adorni for more information on how to proceed.

Berger Montague's Commitment

Established in 1970, Berger Montague has a long history of advocating for investors and has handled numerous high-profile securities class action cases. With offices in major U.S. cities including Philadelphia, Minneapolis, and San Francisco, the firm has dedicated decades to representing both individual and institutional investors. Their experience spans various industries, and they are well equipped to navigate the complexities of class action lawsuits.

Conclusion

With Altimmune Inc. facing turbulent waters following its recent trial results, affected investors have a key opportunity to stand up for their rights through this class action. The actions taken by Berger Montague PC highlight the essential role of legal advocacy in addressing corporate accountability and protecting the interests of shareholders. For those considering involvement in this case, swift action is advised to secure their place in the proceedings.